- RecruitingPHASE2
Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
This study looks at a new way to treat early-stage Hodgkin Lymphoma using a drug called Tislelizumab. The goal is to find an effective treatment that causes fewer side effects than traditional chemotherapy and radiation, especially for younger patients.
For: Classical Hodgkin LymphomaGermany - RecruitingPHASE2
Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.
This study looks at adding a new drug, Tislelizumab, to standard treatment for advanced bowel cancer. It aims to see if this combination can help more people avoid surgery in the long term, by making the existing treatment even more effective.
For: Locally Advanced Rectal Cancer (LARC)Germany · Israel - Active not recruitingPHASE3
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
This study looks at the long-term safety of a drug called zanubrutinib for people with certain blood cancers (B-cell malignancies). It's for those who have already taken zanubrutinib in a previous study.
For: B-cell MalignanciesUnited States · Australia · China - Active not recruitingPHASE3
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study looks at a new drug, zanidatamab, combined with chemotherapy, and sometimes another drug called tislelizumab. It aims to see if this treatment works better and is safer than standard chemotherapy for advanced stomach and gullet cancers that have HER2.
For: Gastric Neoplasms · Gastroesophageal Adenocarcinoma · Esophageal AdenocarcinomaArgentina · Australia · Belgium - RecruitingPHASE3
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
This study looks at new treatments for advanced lung cancer that has stopped responding to previous therapies. It compares a new drug combination with standard chemotherapy to see if it's more effective and safe for patients who have already tried other treatments.
For: NSCLC Stage IVUnited States · Canada · United Kingdom - Active not recruitingPHASE2
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
This study is looking at a new treatment called tislelizumab, sometimes combined with other medicines, for head and neck cancer that has come back or spread. The aim is to see if it can shrink tumours and if it's safe for patients.
For: Head and Neck Squamous Cell Carcinoma · Head and Neck CancerUnited States · Australia · Canada - RecruitingPHASE1
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
This study is testing a new combination treatment for stomach or gullet cancer that can be removed with surgery. It combines a drug called Tislelizumab with standard chemotherapy (FLOT) given before the operation. We want to see if this new approach is safe and works well.
For: Esophagogastric Junction Adenocarcinoma · Gastric Adenocarcinoma · Esophageal AdenocarcinomaGermany - RecruitingPHASE2
Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Transformation
This study is looking at new drug combinations for a type of blood cancer called Richter Transformation. It aims to see if two existing drugs, zanubrutinib and tislelizumab, with or without a new drug, sonrotoclax, can safely and effectively treat patients aged 18 and over.
For: Richter TransformationAustria · Denmark · Germany - RecruitingPHASE2
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
This study is testing two new drug combinations for advanced bowel cancer that has spread, but not actively to the liver. It aims to see if a new combination of two medicines, Fruquintinib and Tislelizumab, works better than standard treatment for this type of cancer.
For: Metastatic Colorectal CancerAustria · Germany